

DISCUSSIONS WITH LEADERS

- 185** Advancing Clinical Trial Innovation in Pancreatic Cancer: A Conversation Between Diane Simeone, Ken Herrmann, and Johannes Czernin

Diane M. Simeone, Ken Herrmann, and Johannes Czernin

THE STATE OF THE ART

- 188** Artificial Intelligence in Nuclear Medicine: Opportunities, Challenges, and Responsibilities Toward a Trustworthy Ecosystem

Babak Saboury, Tyler Bradshaw, Ronald Boellaard, Irène Buvat, Joyita Dutta, Mathieu Hatt, Abhinav K. Jha, Quanzheng Li, Chi Liu, Helena McMeekin, et al.

HOT TOPICS

- 197** Whole-Body PET Imaging: A Catalyst for Whole-Person Research?

Lalith Kumar Shiyam Sundar, Marcus Hacker, and Thomas Beyer

ISSUES AND CONTROVERSIES

- 200** Scientific Fraud, Publication Bias, and Honorary Authorship in Nuclear Medicine

Thomas C. Kwee, Maan T. Almaghrabi, and Robert M. Kwee

PROCEDURE STANDARD

- 204** SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors

Thomas A. Hope, Martin Allen-Auerbach, Lisa Bodei, Jeremie Calais, Magnus Dahlbom, Lisa K. Dunnwald, Michael M. Graham, Heather A. Jacene, Courtney Lawhn Heath, Erik S. Mittra, et al.

THERANOSTICS

Clinical

- 211** ■ **FEATURED ARTICLE OF THE MONTH.** Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients Receiving Concomitant ²²⁵Ac-DOTATATE-Targeted α -Therapy and Capecitabine: A Real-World-Scenario Management-Based Long-Term Outcome Study

Sanjana Ballal, Madhav P. Yadav, Madhavi Tripathi, Ranjit Kumar Sahoo, and Chandrasekhar Bal

- 219** ■ **INVITED PERSPECTIVE.** The Future of Targeted α -Therapy Is Bright, but Rigorous Studies Are Necessary to Advance the Field

Jonathan Strosberg, Ken Herrmann, and Lisa Bodei

- 221** Evaluation of ¹⁷⁷Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective ¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)

Sarenya Pathmanandavel, Megan Crumbaker, Bao Ho, Andrew O. Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Adam Hickey, Peter Eu, et al.

- 227** Eligibility for ¹⁷⁷Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of ⁶⁸Ga-PSMA-11 and ^{99m}Tc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer

Gary J.R. Cook, Wai-Lup Wong, Bal Sanghera, Stephen Mangar, Amarnath Challapalli, Amit Bahl, Paul Bassett, Darren Leaning, and Christian Schmidkonz

Translational

- 232** ■ **FEATURED TRANSLATIONAL SCIENCE ARTICLE.** ⁶⁸Ga-DOTATATE Prepared from Cyclotron-Produced ⁶⁸Ga: An Integrated Solution from Cyclotron Vault to Safety Assessment and Diagnostic Efficacy in Neuroendocrine Cancer Patients

Sébastien Tremblay, Jean-François Beaudoin, Ophélie Bélissant Benesty, Samia Ait-Mohand, Véronique Dumulon-Perreault, Étienne Rousseau, Éric E. Turcotte, and Brigitte Guérin

ONCOLOGY

Clinical

- 239** Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PROLoG Consensus Initiative (Part 2—Technical)

Fabien Ricard, Sally Barrington, Ron Korn, Guenther Brueggenwerth, Judith Trotman, Bruce Cheson, Gilles Salles, Larry Schwartz, Greg Goldmacher, Rudresh Jarecha, et al.

- 244** Static and Dynamic ⁶⁸Ga-FAPI PET/CT for the Detection of Malignant Transformation of Intraductal Papillary Mucinous Neoplasia of the Pancreas

Matthias Lang, Anna-Maria Spektor, Thomas Hielscher, Jorge Hoppner, Frederik M. Glatting, Felix Bicu, Thilo Hackert, Ulrike Heger, Thomas Pausch, Ewgenija Gutjahr, et al.

- 252** Prospective Phase II Trial of [⁶⁸Ga]Ga-NODAGA-E[c(RGDyK)]₂ PET/CT Imaging of Integrin $\alpha_v\beta_3$ for Prognostication in Patients with Neuroendocrine Neoplasms

Esben Andreas Carlsen, Mathias Loft, Annika Loft, Dorota Czyzewska, Mikkel Andreassen, Seppo W. Langer, Ulrich Knigge, and Andreas Kjaer

CARDIOLOGY

Clinical

- 260** Precision of Myocardial Blood Flow and Flow Reserve Measurement During CZT SPECT Perfusion Imaging Processing: Intra- and Interobserver Variability

Matthieu Bailly, Frédérique Thibault, Gilles Metrard, Maxime Courtehoux, Denis Angoulvant, and Maria Joao Ribeiro

NEUROLOGY

Clinical

- 266** Early-Phase ¹⁸F-Florbetapir and ¹⁸F-Flutemetamol Images as Proxies of Brain Metabolism in a Memory Clinic Setting

Cecilia Boccalini, Débora Elisa Peretti, Federica Ribaldi, Max Scheffler, Sara Stampacchia, Szymon Tomczyk, Cristelle Rodriguez, Marie-Louise Montandon, Sven Haller, Panteleimon Giannakopoulos, et al.

274 Differential Effects of Tau Stage, Lewy Body Pathology, and Substantia Nigra Degeneration on ¹⁸F-FDG PET Patterns in Clinical Alzheimer Disease

Jesús Silva-Rodríguez, Miguel A. Labrador-Espinosa, Alexis Moscoso, Michael Schöll, Pablo Mir, and Michel J. Grothe; for the Alzheimer's Disease Neuroimaging Initiative

281 Longitudinal Tau PET Using ¹⁸F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters

Denise Visser, Hayel Tuncel, Rik Ossenkoppele, Maqsood Yaqub, Emma E. Wolters, Tessa Timmers, Emma Weltings, Emma M. Coomans, Marijke E. den Hollander, Wiesje M. van der Flier, et al.

287 Investigating Tau and Amyloid Tracer Skull Binding in Studies of Alzheimer Disease

Shaney Flores, Charles D. Chen, Yi Su, Aylin Dincer, Sarah J. Keefe, Nicole S. McKay, Angela M. Paulick, Gloria Guzman Perez-Carrillo, Liang Wang, Russ C. Hornbeck, et al.

294 ■ SPECIAL CONTRIBUTION. The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification

Anne M. Smith, Nancy A. Obuchowski, Norman L. Foster, Gregory Klein, P. David Mozley, Adriaan A. Lammertsma, Richard L. Wahl, John J. Sunderland, Jean-Luc Vanderheyden, Tammie L.S. Benzinger, et al.

AI/ADVANCED IMAGE ANALYSIS

Clinical

304 Clinical Decision Support for Axillary Lymph Node Staging in Newly Diagnosed Breast Cancer Patients Based on ¹⁸F-FDG PET/MRI and Machine Learning

Janna Morawitz, Benjamin Sigl, Christian Rubbert, Nils-Martin Bruckmann, Frederic Dietzel, Lena J. Häberle, Saskia Ting, Svjatlana Mohrmann, Eugen Ruckhäberle, Ann-Kathrin Bittner, et al.

RADIOBIOLOGY/DOSIMETRY

Clinical

312 Fetal Dose from PET and CT in Pregnant Patients

Christiane Sarah Burton, Kirk Frey, Frederic Fahey, Mark S. Kaminski, Richard K.J. Brown, Judith M. Pohlen, and Barry L. Shulkin

Translational

320 First-in-Humans Evaluation of Safety and Dosimetry of ⁶⁴Cu-LLP2A for PET Imaging

Richard Laforest, Anchal Ghai, Tyler J. Fraum, Reiko Oyama, Jennifer Frye, Helen Kaemmerer, Greg Gaehle, Tom Voller, Cedric Mpoy, Buck E. Rogers, et al.

329 Lesion Quantification Accuracy of Digital ⁹⁰Y PET Imaging in the Context of Dosimetry in Systemic Fibroblast Activation Protein Inhibitor Radionuclide Therapy

David Kersting, Walter Jentzen, Daniel Jeromin, Ilektra-Antonia Mavroei, Maurizio Conti, Florian Büther, Ken Herrmann, Christoph Rischpler, Rainer Hamacher, Wolfgang P. Fendler, et al.

ILLUSTRATED POST

Clinical

337 First-in-Humans PET/MRI of In Vivo GD2 Expression in Osteosarcoma

Nils Florian Trautwein, Gerald Reischl, Christian Seitz, Helmut Dittmann, Ferdinand Seith, Sophia Scheuermann, Tobias Feuchtinger, Frank Dombrowski, Rupert Handgretinger, Jörg Fuchs, et al.

LETTERS TO THE EDITOR

339 Dosimetry in Radiopharmaceutical Therapy

Michael Stabin

339 Reply: Dosimetry in Radiopharmaceutical Therapy

Joe O'Donoghue, Pat Zanzonico, John Humm, and Adam Kesner

DEPARTMENTS

8A This Month in JNM

341 Book Review

342 In Memoriam